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ABSTRACT: The safety of food produced from genetically engineered (GE) crops is assessed for potential risks of food allergy
on the basis of an international consensus guideline outlined by the Codex Alimentarius Commission (2003). The assessment
focuses on evaluation of the potential allergenicity of the newly expressed protein(s) as the primary potential risk using a process
that markedly limits risks to allergic consumers. However, Codex also recommended evaluating a second concern, potential
increases in endogenous allergens of commonly allergenic food crops that might occur due to insertion of the gene.
Unfortunately, potential risks and natural variation of endogenous allergens in non-GE varieties are not understood, and risks
from increases have not been demonstrated. Because regulatory approvals in some countries are delayed due to increasing
demands for measuring endogenous allergens, we present a review of the potential risks of food allergy, risk management for food
allergy, and test methods that may be used in these evaluations. We also present new data from our laboratory studies on the
variation of the allergenic lipid transfer protein in non-GE maize hybrids as well as data from two studies of endogenous allergen
comparisons for three GE soybean lines, their nearest genetic soy lines, and other commercial lines. We conclude that
scientifically based limits of acceptable variation cannot been established without an understanding of natural variation in non-GE
crops. Furthermore, the risks from increased allergen expression are minimal as the risk management strategy for food allergy is
for allergic individuals to avoid consuming any food containing their allergenic source, regardless of the crop variety.
KEYWORDS: genetically modified, IgE, food allergy, soybean, maize, risk management
■ INTRODUCTION
Genetically Engineered (Genetically Modified) Crops.
We have used the term genetically modified (GM) here as the
more commonly recognized term, but are restricting the
definition to mean those engineered by insertion of a specific
sequence of DNA, rather than the broader genetic
modifications that occur through wide-genetic crosses or
chemical and radiation mutagenesis. Development of a strategy
and regulations for ensuring that foods from GM crops are as
safe as their conventional counterparts occurred before the first
plants were allowed into commercial production. The
foundation of the assessment is the recognition that there is a
long history of safe consumption of commonly consumed plant
species; there is natural variation in the composition of foods
produced from these organisms; and there are specific
nutrients, antinutrients, toxins, and allergens in the commonly
consumed species.1 The safety assessment therefore focuses on
characterizing the intended modification with specific tests for
allergenicity or toxicity required on the basis of scientifically
defensible hypotheses related to the introduced gene, gene
products, and, if generated, metabolites. In addition, potential
unintended effects are to be evaluated on the basis of
agronomic characteristics, compositional analysis, and evalua-
tion of key (species specific) nutrients, antinutrients, allergens,
and toxins.1 Approvals of some specific GM crops for
importation or cultivation have been delayed for years in the
European Union (EU) and some other countries due to
questions related to possible changes in endogenous allergen
levels, even though these same varieties have been approved in
the United States, Canada, and many other countries
(unpublished comparison of approvals recorded at www.cera-
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gmc/org for global approvals vs www.GMO-Compass.org for
EU approvals). We are not aware of any adverse human health
events that have occurred due to the consumption of foods
produced from any approved GM event. Yet the search for
even minor differences between every new GM and its nearest
genetic relative continues. Therefore, we have provided a brief
review of the genetic and compositional complexity of the host
plants (gene recipient), modification methods, review risks of
food allergy, and present new data from three of our studies
evaluating natural variation in endogenous allergens in maize
and in soybean to consider the relevance for evaluating
endogenous allergen levels in GM crops as part of regulatory
requirements.
Overview of GM Crop Development. The first
commercial production of GM crops developed and approved
for use in food, feed, and fiber was in 1996, primarily in the
United States and in Canada, Argentina, and Australia.2 These
GM plants were developed by transformation of commonly
used food crop varieties by insertion of relatively short
segments of DNA encoding from one to a few proteins from
naturally occurring bacteria or plant sources. Expression of the
introduced genes has provided increased resistance to specific
insects, tolerance to commonly used herbicides, resistance to
specific viruses, or delayed ripening of soft fruits.3 Although
hundreds of different GM plants have been partially or fully
developed, a few traits dominate the commodity market, have
been bred into genetically diverse varieties, and have been
widely adopted in many additional countries. Approved GM
crops were grown on approximately 160 million hectares in 29
countries in 2011.4
Understanding the source of genetic diversity in GM plants
requires an appreciation of inherent genetic diversity in non-
GM plant species as well as a comparison of the methods of
genetic engineering to other methods used to introduce new
traits. Biolistic methods or more commonly a genetically
modified infectious Agrobacterium tumefacians transformation
binary vector system has been used to introduce the desired
gene (DNA) into the host plant (www.cera-gmc/org).
Transformed organisms such as soybean and maize have
genomes that include between 10000 and 40000 genes,
organized on multiple chromosomes that include more
noncoding DNA than coding DNA. Thus, randomly inserted
DNA has a very small chance of altering the expression of any
single endogenous gene as altered expression is only likely if the
insertion is in proximity to the coding region of a gene or gene
promoter or if the inserted gene is a very strong transcriptional
factor with plausible regulatory impact on genes encoding
specific allergens. The developer will know whether the gene
encodes a transcriptional factor through characterization of
donor DNA and products. In the process of producing effective
new GM crop varieties, thousands of transformed cells and
plants fail to develop or are discarded as they do not grow
normally or produce viable seeds because biologically important
genes have been interrupted. Thus, the majority of genetically
and phenotypically perturbed transgenic plants are removed as
candidates for further development very early in the process.
Developers also select plants that contain only a single DNA
insert if at all possible during molecular characterization of the
transformed plants. Plants are usually backcrossed to achieve
true breeding, nearly homozygous breeding stock that is
functionally similar to the original pretransformed parental line,
with the exception of the inserted transgene(s). However, often
a small percentage of genes will vary between the parental line,
the transformed plant, and progeny as the parental line is rarely
completely homozygous at all loci. The selected GM plants are
tested for gene stability, performance under various field
conditions, and production of nutrients that are typical of the
specific crop to ensure performance. Following the proof of a
specific GM trait is useful; it will likely be bred into plants with
diverse genetic backgrounds to provide optimum production
when grown in very different environments in North and South
America, Asia, Australia, Africa, and Europe. Plant geneticists
have only relatively recently begun to be able to document and
fully understand the genetic differences that exist in similar-
appearing varieties of the same species. The maize genome is
thought to include roughly 20500 genes.5 There are few data
comparing genomes of varieties of crops. However, a genome
and breeding study of two inbred maize lines, B73 and Mo17,
estimated a complete comparison would show up to 10000
short, nonshared genetic fragments or chromosomal rearrange-
ments between the inbred lines. However, following cross-
pollination, the hybrids produce higher yields, with larger ears,
and the plants are adapted to more diverse growing conditions.5
Grain from these hybrids is used for food and feed purposes
similar to uses of grain from the individual inbred parents. The
soybean genome includes more than 10000 protein coding
genes.6 Although Glycine max (cultivated soybean) and Glycine
soja (wild soybean) have many divergent genes and are
generally self-pollinated, the plants can be manually cross-
pollinated and produce viable progeny.6 Wide genetic crosses
with wild relatives, such as G. max and G. soja, provide genetic
diversity that may be useful to introduce disease and stress
resistance, but their introduction requires many rounds of
backcrossing and selection to regain high-yielding agronomic
properties of elite lines. The introduction of such genetic
variants is highly likely to introduce minor phenotypic variation
in the expression of many proteins including allergens and
antinutrients, but those are rarely measured and not regulated.
In addition, variable environmental factors including water
availability, temperature, insolation, wind, soil nutrients, and the
presence or absence of symbionts or pathogens can modulate
gene expression and accumulation of proteins and metabolites.7
An important consideration for breeders is whether the major
nutritional and agronomic traits of new varieties provide
acceptable yields and characteristics under the conditions for a
given agricultural production area. The “natural” genetic and
phenotypic variation that exists in agricultural production
should be considered in the evaluation of new GM varieties for
acceptability according to Codex (2003).1
Food Safety Paradigm. The goal of the food safety
assessment is a determination that the GM crop food material
is either substantially equivalent to the non-GM counterpart in
terms of food safety or that it is unacceptably more hazardous
or “risky” under common growth and processing conditions. It
has long been recognized that no food can be judged 100% safe
or without risk for all humans under any conceivable use.
Gluten proteins in wheat, barley, and rye cause celiac disease
(CD), which affects nearly 1% of the global population.8
Production of most conceivable GM wheat varieties would not
be expected to alter the risk of eliciting symptoms of CD unless
the GM trait introduced a new gliadin or glutenin or knocked
out one or more of the CD-eliciting genes. Similarly, peanuts,
soybeans, wheat, and maize cause food allergy for a number of
consumers. Collectively, approximately 4% of consumers (2−
4% adults, 6−8% of children) in the United States, EU, and
Japan experience food allergy due to the development of
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specific IgE antibodies to one or more proteins in the major
sources of food allergy, including these commodity crops. The
prevalence of food allergy to the major food allergens in the
United States is estimated primarily by carefully structured,
detailed telephone surveys. Results of a validated and widely
cited survey indicate that peanut allergy affects approximately
1% of young children and 0.6% of adults; tree nut allergy affects
0.5% of children and 0.6% of adults; cow’s milk allergy affects
2.5% of young children and 0.3% of adults; chicken egg allergy
affects 1.5% of children and 0.2% of adults; fish allergy affects
0.1% of children and 0.4% of adults, crustacean shellfish allergy
affects 0.1% of children and 2% of adults; and soybean and
wheat allergies affect ∼0.4% of children and 0.3% of adults in
the United States.9 Mustard, celeriac, and lupin are also cited as
common allergenic food sources in some countries of the EU as
reported by Ventor and Arshad.10 Additionally, buckwheat is
cited as a major allergenic food crop for Japan.11
Any GM variety would be expected to cause similar food
allergies (same people; similar severity symptoms) as the non-
GM counterpart and pose the same risks for the same
consumers. Those with celiac or food allergy must avoid the
foods that cause their disease whether the food is produced
from a GM or traditionally bred variety (Codex, 2003).1
Commodities produced and sold around the world for food
production are not segregated on the basis of high or low
allergy elicitation. Rather, they are produced from harvests that
include many varieties which change in availability and are
often comingled. Importantly, the amount of allergenic food
components may also vary markedly in processed foods,
altering exposure, but in most countries foods must be labeled
listing the contents (e.g., peanut, wheat, eggs), but not the
quantities of these materials that are present.
New GM crops are tested more rigorously under regulatory
scrutiny than crops modified by intentional or natural
mutagenesis and those produced by crossing with wild relatives
to introduce new plant traits such as disease resistance, drought
tolerance, or other improved characteristics. The allergenicity
assessment process recommended by Codex (2003)1 was
reviewed by Goodman et al.12 The risk is for those with existing
allergies with the focus on preventing the transfer of an
allergenic protein into a new source that would not be
recognized by the allergic consumer. Additionally, the transfer
of a protein that is nearly identical to an allergen would present
a risk of allergic cross-reactions that require testing if the
sequence identity match of the introduced protein is high using
computer alignment comparison to known allergens.12 If
needed, specific serum tests are used to evaluate IgE binding.
If the introduced protein in the new GM crop shows evidence
that it is an allergen or is highly likely to be cross-reactive, it is
unlikely to be acceptable for regulators as consumers would not
expect to find their allergen in foods made with a plant that
should not contain their allergen.
In addition, the stability of the protein in pepsin and
abundance are also considered in the risk evaluation as a
number of common food allergens are stable and abundant.
Regulators are hesitant to approve GM crops with new
abundant, pepsin-stable proteins due to the suspicion of a
higher risk of sensitization or elicitation by such proteins.
Finally, there is a hypothetical concern that transformation may
induce increases in the expression of endogenous allergens,
increasing risks for those with allergies or increasing the chance
of sensitization, yet this has turned into the major focus of the
allergenicity assessment in some countries.
Compositional “Substantial Equivalence” Including
Allergens. In addition to evaluating the safety of the new trait,
food and feed materials from the new GM plant varieties are
evaluated for potential changes in the composition of key
nutrients as well as antinutrients, toxins, allergens, and celiac-
eliciting proteins (if the GM plant is wheat or a near-wheat
relative), which are specifically associated with the host plant
(gene recipient). Tests performed to evaluate substantial
equivalence are specific to plants derived from the individual
transformational event. Unfortunately, there are few published
data regarding the concentration of specific allergens or glutens
found in different genetic backgrounds (varieties). Even fewer
data are available from studies designed to evaluate environ-
mental variation found in plants of the same variety grown in
different locations or years. A few published studies suggest that
certain allergenic food proteins are highly variable in abundance
in some crops as reviewed by Goodman et al.12 The
concentration of lipid transfer protein (LTP), also referred to
as Mal d 3, an allergen in apples that is reported to cause severe
reactions in Spain, was found to vary in concentration by
approximately 100-fold across 88 apple cultivars.13 We recently
published preliminary data demonstrating up to 15-fold
variation in LTP concentration in grain of nine non-GM
maize hybrids grown without irrigation in a field trial in
Nebraska.14 The publication also included some results of a
study evaluating potential differences in IgE binding to proteins
of a GM soybean line (BPS-CV127, from BASF Plant Science),
a near-isogenic line, and three other commercial soybean lines.
Minor qualitative differences were identified between soybean
lines based on serum IgE immunoblots (one-dimensional
reducing and nonreducing blots using individual sera and by
two-dimensional immunoblots) using individual soybean
allergic sera. However, no significant differences were measured
on the basis of inhibition ELISA tests between extracts using
pooled soybean allergic sera.14
Although the general guidance of Codex (2003)1 for safety
including evaluating potential risks of food allergy is followed
by most countries that approve GM crops, some countries and
the European Food Safety Authority (EFSA) have recently
asked for more detailed studies of potential changes in
endogenous allergens than were performed previously. The
new requests include proteomic analysis or two-dimensional gel
blotting with individual allergic subject’s sera for each new
submission and for food crops that rarely cause allergy.15 Yet in
terms of food safety, there is no scientific basis to demonstrate
what levels of change would pose an unacceptable risk to
allergic consumers.16,17 The senior investigator (Goodman) has
performed serum IgE binding studies on five different GM
soybean events and one GM wheat event since 1999. In each
case it has proven very difficult to obtain sufficient sera from
subjects diagnosed with clear food allergies to soybean or
wheat. Development of appropriate methods, interpretation of
results, and evaluation of minor differences in IgE binding
between the GM event and near-isogenic and representative
commodity food grade materials have proven challenging.
Because there are no standards of acceptable differences or
optimal testing protocols, regulatory evaluation of scientific
studies and data is hard to predict and may vary across
jurisdictions. Therefore, it is important to have a broader
discussion of the variation in prevalence of allergies for GM
crop varieties under consideration, natural variation in allergen
content for material in commerce today, and appropriate
interpretation and risk management strategies.
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As noted, those with food allergy must avoid the source of
their allergies. Most of the foods that are consumed today are
processed in some form and contain highly varied amounts of a
given component (e.g., soybean protein isolate). The protein
isolates may be processed by different methods and are made
from market-available varieties of plants that are grown under
diverse environmental conditions. There is no practical way to
measure and control the allergen dose in each food.
Furthermore, the risk of consuming an allergen is for those
who are sensitized, as other consumers can consume high
amounts of allergenic foods with no adverse effect. The only
practical risk management strategy at this time for those with a
specific allergy is to avoid any food that contains any protein
from the source of their allergic disease.
The prevalence of soybean allergy may be as high as 0.4% in
children and 0.3% in adults. Reactions to soybeans are rarely
life-threatening. There are fewer than five documented cases of
fatal food allergic reactions to soybean from a Swedish allergy
group.18 No other reports of fatalities were found in the
literature, although some other severe systemic allergic
reactions are documented.19 There are three dominant soybean
allergenic protein classes, glycinins, β-conglycinins, and a
pathogenesis-related protein that cross-reacts with a birch
pollen allergen,20−22 but little is known about the variability of
expression of these proteins between varieties, environmental
growing conditions, or variation due to food processing.
New Studies in Maize and Soybean. Food allergy to
maize is relatively rare, and the only significant reported food
allergen is a nonspecific LTP.23 This paper includes the
complete data summary of a study of maize LTP accumulation
from irrigated and rain-fed conditions and representative results
from three different serum IgE binding studies with multiple
lines of soybeans. The results are discussed in the context of
risk assessment of GM crops.
■ MATERIALS AND METHODS
Maize Lipid Transfer Protein Analysis. Nine commercial non-
GM maize (corn) hybrids were grown at two University of Nebraska
field-trial sites in eastern Nebraska with irrigation (Clay Center) or
with and without irrigation (Mead). Commercial hybrid samples
DKC61-73, DKC60-19, N70-F1, N60-B6, N76-D3, N69-P9, DKC50-
20, Mo17-B73, and DKC63-46 were grown at both sites and
conditions, with duplicate plots for most samples (Table 1).
Evaluation of the LTP content of grain was performed by Harsha
Ariyarathna as part of her master’s thesis (unpublished results). Three
independent 10 g samples of grain from each plot were individually
ground to a fine powder under liquid nitrogen, and proteins were
extracted at 4 °C in 25 mM sodium acetate (pH 4.0) buffer and
clarified by filtration, similar to the method of Pastorello et al.23 The
total protein content of extracts was determined by Lowry assay, and
samples were adjusted to 5 mg/mL protein and 1% β-mercaptoethanol
and then heated to ∼90 °C. Samples of serially diluted, 95% pure
natural maize LTP (mLTP) characterized by LC-MSMS with 95%
sequence coverage were prepared in a similar manner, but diluted in
0.1% bovine serum albumin (BSA) as carrier protein and β-
mercaptoethanol added to 1% by volume. Two microliters of diluted
mLTP standard and maize extract samples were spotted in triplicate
on 0.45 μm pore size nitrocellulose membranes immediately after
heating (95 °C) and cooling to room temperature. Membranes were
blocked with 5% nonfat dry milk (NFDM) in phosphate-buffered
saline with 0.2% Tween 20 (PBST) prior to incubation with mLTP
peptide-specific (AARTTADRRA, corresponding to amino acids 67−
76 of mLTP) diluted rabbit polyclonal IgG.14 Excess IgG was removed
by washing in PBST. Bound IgG was detected using diluted goat anti-
rabbit IgG−horseradish peroxidase (Pierce Chemical, Rockford, IL,
USA) in NFDM blocker. Following removal of unbound IgG, ECL
Pico-west substrate solution (Pierce Chemical) was added to
membranes, and approximately 2 min later emitted light was captured
using a Kodak Gel Logic 440 imaging system. The pixel densities of
sample and standard spots of images captured at the same time were
used to compare sample extract immunospot densities to those of
known concentrations of the diluted mLTP standard. Standard curves
and correlation coefficients were calculated using Microsoft Office
Excel 2007 software for each standard curve (in triplicate). Mean
sample values (n = 6 for most or n = 3 for three samples) for each
hybrid, growing condition, and location were compared using one-way
analysis of variance (ANOVA). Fisher’s protected least significance
difference method (LSD) was used to determine which hybrids were
statistically different using Statistical Analysis Software (SAS) version
9.1 (SAS Institute, Cary, NC, USA).
Soybean Samples for Endogenous Allergenicity Compar-
isons. Samples. Soybean seed samples were supplied from study
sponsors (BASF Plant Science and Bayer CropScience) to compare
IgE binding to endogenous soybean allergens for three different GM
soybean lines, their non-GM, near-isogenic line (null-segregant sibling
or parental lines), and multiple non-GM commercial lines, in separate
studies (Table 2). Representative data from the BASF study (data not
previously reported by Panda et al.)14 and the two Bayer studies are
presented to demonstrate the complexity, variation, and challenges of
performing and interpreting such tests. Samples of soybeans were
supplied as dehulled, defatted flour samples, certified as to identity by
the study sponsors. Control samples of uncooked navy bean (Phaseolus
vulgaris) and peanut (Arachis hypogaea) were purchased at local
markets, ground to a fine powder, and stored frozen prior to
extraction. Samples of dried corn grain (Zea mays) were obtained from
a previously described field trial.14
Table 1. mLTP Content in Nine Maize Hybrid Grain Samples from Mead and Clay Center, NE, with or without Irrigation
Mead, NE Mead, NE Clay Center, NE
irrigated rain-fed irrigated ratio:
hybrid maize (av mg/g, SD)a (av mg/g, SD)a (av mg/g, SD)a high/low
DKC50-20 4.36, 0.67b 7.42, 1.77c 3.65, 0.29c 2.03
DKC60-19 5.23, 0.42c 8.70, 1.91c 4.27, 0.52c 2.04
DKC61-73 2.43, 0.36c 0.66, 0.01c 1.70, 0.11b 3.68
DKC63-46 1.82, 0.46c 3.66, 1.27c 1.47, 0.16c 2.49
Mo17xB73 3.32, 0.58c 5.74, 0.88b 2.03, 0.18c 2.83
N60-B6 4.68, 0.41c 6.24, 1.65c 3.43, 0.82c 1.82
N69-P9 3.40, 0.44c 9.86, 2.01c 2.72, 0.15c 3.63
N70-F1 1.15, 0.10c 7.90, 1.60c 1.50, 01.5c 6.87
N76-D3 2.80, 0.77c 3.76, 1.95c 2.55, 0.40c 1.47
ratio: high/low 4.55 14.94 2.90
aAverage content is reported in mg mLTP per g total protein, standard deviation (SD, rounded). bSample size is 3 (1 plot, 3 replicates). cSample size
is 6 (2 plots, 3 replicates).
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Human Serum and Plasma Samples. Human donor samples were
provided from clinical sources collected following informed consent
and under ethical review at allergy clinics associated with the
University of Zurich (Zurich, Switzerland) or Charity Hospital (Berlin,
Germany) with summaries of clinical diagnosis or from FDA-licensed
blood product collection centers (PlasmaLab, International, Everett,
WA, USA) or SeraCare Life Sciences (Milford, MA, USA) with self-
reported allergies and in vitro IgE ImmunoCAP values determined for
whole-soybean antigen mixture. Donor samples were coded by
suppliers and were never revealed to us. Descriptions of clinical
histories of allergies and available clinical allergen-specific IgE test
results (if available) were provided with samples (Table 3). We further
screened serum and plasma samples by in vitro IgE immunoblotting to
a non-GM soybean extract to select appropriate, informative donors
for use in the studies. In some cases, food challenge positive subjects
had no detectable IgE binding in our tests, whereas some with less
certain allergic status showed strong in vitro IgE binding that may
indicate sensitization without allergy or cross-reactivity with or without
clinical symptoms.
One-Dimensional Immunoblots. Proteins of soybean and control
samples were extracted (1:10 w/v) in phosphate-buffered saline (pH
7.2) with protease inhibitors as described previously.14 Protein
concentrations were determined using the Lowry method, and equal
total protein concentration samples were separated using one-
dimensional SDS-PAGE Tris−glycine 7 cm minigels in either reducing
or nonreducing Laemmli buffer, with or without heating (respectively).
Running buffer was 25 mM Tris, 0.192 M glycine, pH 8.3, 0.1% SDS.
Proteins were then electrophoretically transferred to PVDF mem-
branes prior to blocking in 2% nonfat dry milk (NFDM) and
incubation with serum or plasma samples diluted in PBST with 2%
NFDM (1:10 or 1:20, v/v) as described previously.24,25 Bound IgE
was detected by electrochemical luminescence (ECL) using
monoclonal anti-human IgE conjugated with horseradish peroxidase
(SouthernBiotech, Birmingham, AL, USA) diluted 1:1000, followed by
ECL substrate (SuperSignal West-Dura, Thermo Scientific) as
described previously.14 Images of blots incubated with the same
serum or plasma sample and separation procedure (reducing or
nonreducing) were captured simultaneously along with a standard
dilution series of purified human IgE, using a Kodak Gel Logic Image
Station 440 (CareStream Health, Rochester, NY, USA). The specificity
of the SouthernBiotech monoclonal anti-hIgE-HRP (clone B3102E8;
Table 2. Soybean Samples Provided by Study Sponsors To










GM BPS-CV127-9a LL55b FG72c
(designation) (3411-T) (A5547-A127)
near isogenic null-segregant near isogenic parental
(designation) (3410-I) (A5547) (Jack)
commercial MON8001 Stine 2686-6 Stine 2686-6
(designation) (3415-M) (D) (D)
commercial CD217 Stine 2788 Stine 2788
(designation) (3416-C) (E) (E)
commercial Conquesta Stine 3000-0 Stine 3000-0
(designation) (parental line) (F) (F)
aEvent BPS-CV127-9 is tolerant to imidazolinone herbicides due to
insertion of a gene encoding a modified acetohydroxy acid synthase
protein from Arabidopsis thaliana. bLL55 is a GE soybean that is
tolerant to glufosinate ammonium herbicides due to insertion of a
gene encoding a modified phosphinothricin acetyltransferase protein
from Streptomyces viridochromogenes. cEvent FG72 is tolerant to
glyphosate and isoxaflutole herbicides due to insertion of genes
encoding a modified maize (Zea mays) 5-enolpyruvylshikimate-3-
phosphate synthase (EPSPS) protein and a modified p-hydroxyphe-
nylpyruvate dioxygenase (HPPD W336) protein from Pseudomonas
f luorescens.
Table 3. Serum and Plasma Samples Used To Evaluate IgE Binding in Three Studies (Donor No.; Clinician- or Self-Proclaimed
History of Food Allergies; Soybean-Specif ic IgE by ImmunoCAP If Known, kU/L)
BASF Plant Science BPS-CV127-9 (3411T) Bayer CropScience 1 LL55 Bayer CropScience 2 FG 72
714; soybean, wheat, corn, milk, pollen, HDM; 16 kU/L 9735-RE; soybean, peanut; 5 kU/L 9735-RE; soybean, peanut; 5 kU/L
715; soybean, peanut, lentils, hazelnut, apple, carrots, pollen,
HDM; 17 kU/L
715; soybean, peanut, lentils, hazelnut, apple, carrots,
pollen, HDM; 17 kU/L
CC 03; soybean, peanut, fish, walnut,
peppers; >1 kU/L
716; soybean, shrimp, clam, pollen; 7 kU/L 716; soybean, shrimp, clam, pollen; 7 kU/L CC 04; soybean, peanut, walnut, celeriac,
pollen; 0.6 kU/L
719; soybean, wheat, peanut; 21 kU/L 17006-RM; soybean, peanut; 7.8 k/L CC 08; soybean, peanut, almond, walnut,
celeriac; >1 kU/L
721; peanut, corn, wheat; 47 kU/L 18534-LN; nuts, beans, seeds; 17.3 k/L CC 10; soybean, peanut, milk, almond,
walnut, celeriac; 7 kU/L
RGLEG103; peanut, cashew, pecan, walnut, Brazil nut,
almond, mold, pollen; 12 kU/L
19392-CS; nuts, beans, seeds; 72 kU/L 19392-CS; nuts, beans, seeds; 72 kU/L
RGLEG118; soybean, peanut, cashew, Brazil nut, pecan,
almond, crustaceans; 7 kU/L
20197-BH; nuts and raw vegetables; 3 kU/L 20197-BH; nuts and raw vegetables; 3 kU/L
RELEG105; peanuts, walnut, celery, cashew, pollen; 2 kU/L 20770-MH; nuts, beans, seeds; soybean; peanut,
throat swelling; 16.4 k/L
CC 15; soybean, lentil, peanut, almond; 1
kU/L
LPSCH102; soybean, peanut, walnut, hazelnut, celeriac,
apple, kiwi, pollen; 2 kU/L
22206-DL; nuts, beans, seeds; 7.85 k/L CC 11; peas, carrot, almond, walnut, cherry,
celeriac; 0.1 kU/L
RG68; soybean; 4 kU/L 22329-JE; no recorded history of allergy; 8.58 kU/L CC 12; peanut, carrot, almond, celeriac,
fruits; 0.1 kU/L
RG77; soybean; 8 kU/L CC 16; carrot, hazelnut, apple, food
challenges pollen; 0.04 kU/L
Not Soybean Allergic (Controls)
CTL 712; NA; NA CTL SNP; no known allergies CTL SNP; no known allergies
CTL RG71; lupine; 1.5 kU/L CTL RG71; lupine; 1.5 kU/L CTL RG71; lupine; 1.5 kU/L
CTL RG73; pea, 0.7 kU/L CTL RG73; pea; 0.7 kU/L CTL RG73; pea; 0.7 kU/L
CTL RG 74; lupine, peanut; <0.35 kU/L CTL RG74; lupine, oral allergy syndrome to peanut;
<0.35 kU/L
CTL RG74; lupine, oral allergy syndrome to
peanut; <0.35 kU/L
CTL 287; soybean, peanut; <1 kU/L
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9160-05) was verified by reciprocal binding to diluted human
myeloma IgE (ABCAM Laboratories, Cambridge, MA, USA;
AB65866-1), and purified IgG (Sigma 12511) as compared to binding
with a monoclonal hIgG-HRP (SouthernBiotech clone 9042-05).
Two-Dimensional Immunoblots. Ground raw soybean seed
samples were first extracted using the trichloroacetic acid/cold acetone
precipitation method of Natarajan et al.,26 modified as described
previously14 using 8 M urea and 2% CHAPS to extract protein. The
protein content of clarified extracts was determined by using the
Bradford assay (Bio-Rad, Hercules, CA, USA). Samples representing
25 μg of extracted protein were diluted in 125 μL of isoelectric
focusing buffer [8 M urea, 2% CHAPS, 50 mM DTT (Thermo
Scientific, Rockford, IL, USA), containing 0.5% ampholyte pH 3−10
(Bio-Rad)] and applied to 7 cm pH 3−10 nonlinear IPG strips from
Bio-Rad for isoelectric focusing as described previously.14 Proteins in
focused strips were reduced and acetylated and then separated on the
basis of apparent molecular mass in the second dimension in NuPAGE
Novex 4−12% Bis-Tris ZOOM gels (Invitrogen). Following electro-
phoresis, either the gels were stained using Coomassie blue stain or
proteins were electro-transferred to PVDF membranes for immuno-
blotting and detection of bound IgE using ECL substrate sera as
described for 1D immunoblotting.
Direct ELISA. Direct binding enzyme-linked immunosorbent assays
(ELISA) to soybean proteins were performed to qualify human blood
samples (serum or plasma) for all studies using individual sera with
pooled soybean samples as the antigen target. Ground soybean seeds
(either defatted or full-fat) were extracted 1:10 w/v in pH 7.4
phosphate-buffered saline (PBS), and protein content was determined
according to the Lowry method and then diluted to 10 μg protein/mL
in pH 9.6 carbonate−bicarbonate buffer to coat Maxisorp ELISA
plates (Nunc-Thermo Scientific) overnight at 4 °C. Similar extracts of
peanut, wheat, or maize were used as controls in some assays along
with empty wells to estimate background binding. Wells were washed
with PBS containing 0.05% Tween 20 (polyoxyethylene sorbitan
nonionic detergent, PBST) and then blocked with 1% bovine serum
albumin (BSA) in PBS. Serum and plasma samples were diluted to
between 1:5 and 1:20 v/v in PBS containing 1% BSA for 1 h at 37 °C.
Human samples were diluted on the basis of previous determinations
of soybean-specific IgE levels if data were available. Unbound IgE was
removed by four sequential washes using PBST. Bound IgE was
detected using 1:5000 diluted monoclonal anti-hIgE conjugated with
horseradish peroxidase (SouthernBiotech) followed by four washes
with PBST and then application of TMB substrate (tetramethylbenzi-
dine from Sigma, St. Louis, MO, USA). Absorbance values were
measured in a BioTek instrument Powerwave XS2 (Winooski, VT,
USA).
Inhibition ELISA. Independent competitive serum IgE binding
assays were performed for two of the GM soybean lines (BPS-CV127-
9 from BASF and FG72 from Bayer) to compare binding to their near-
isogenic or parental line counterparts as well as three other commercial
soybean lines. The assay design is similar to that demanded by
pharmaceutical regulators in the EU for testing the equivalence of
potency of allergenic extracts used in diagnosis and immunotherapy
for allergy.27 ELISA plates were coated with pooled soybean extract
pools of the GM, near-isogenic, and commercial lines using
bicarbonate buffer as described for direct ELISA tests. Individual
human blood samples (serum or plasma) for each study were chosen
from subjects with described clinical symptoms to ingestion of soybean
and marked serum IgE binding to soybean proteins demonstrated
during immunoblotting and preliminary direct ELISA assays. The
volumes of individual human samples were chosen on the basis of
diversity of protein binding and strength of binding to ensure
representative IgE specificity and balanced binding strength to
minimize dominance by any individual subject.
■ RESULTS AND DISCUSSION
Maize Lipid Transfer Protein. LTP is produced and
stored in the pericarp of the grain just under the waxy seed coat
as well as throughout the embryo of mature grain (results from
immunohistochemistry in Goodman laboratory, data not
shown). The concentration of mLTP in finely ground whole
grain (approximately 10% moisture) was determined for each
of the nine hybrids from two locations, grown with irrigation or
in one location without irrigation. The average total protein
yield from each 10 g sample of grain ground extracted with
sodium acetate ranged from 8 to 9.5% protein based on the
Lowry protein assay. The mLTP was determined using a
semiquantitative immunodot-blot assay, using equal total
protein (10 μg) replicate samples. The mLTP was detected
using peptide-specific mLTP rabbit IgG that was detected using
HRP-labeled goat anti-rabbit IgG followed by ECL. The mLTP
concentration in grain samples was estimated by comparing
densitometry values of samples to dot blots of standard diluted
purified natural mLTP using regression analysis. The lowest
level of accumulated mLTP was approximately 0.66 mg mLTP/
g total protein and the highest was 9.86 mg mLTP/g total
protein (Table 1). The greatest differences in mLTP
accumulation between all hybrids across sites and treatments
varied over 2.9-fold for Clay Center (irrigated), 4.5-fold for
Mead Center (irrigated), and 14.9-fold for Mead (nonirrigated)
samples. The greatest difference across locations and treat-
ments for any one hybrid was 5.27-fold. These widely divergent
concentrations of mLTP across locations and growing
conditions suggest that normal variation in exposure to the
major maize allergenic protein in foods could easily be expected
to be up to 15-fold difference across genetic and environmental
differences. Because mLTP is considered a pathogenesis-related
protein that may be induced by stress,28 the differences are not
surprising. Food allergy to maize is rarely noted. There are no
published data that demonstrate this wide difference in the
content of mLTP contributes to the risk of allergy to maize
despite the fact that mLTP is the only maize protein known to
be responsible for severe (anaphylactic) reactions following
consumption by corn-allergic subjects.23 On the basis of our
data, one might expect that differences of 5-fold or more in
LTP concentration between a GM corn compared to its nearest
isogenic comparator might occur due to environmental
conditions. Risk management for corn-allergic people is to
avoid consuming any product with corn proteins, regardless of
variety (GM or non-GM) or commercial lot of corn.
Soybean IgE Comparisons. Three independent studies
were performed over a two year period to test relative IgE
binding to the GM soybean lines and nearest genetic relative
(null-segregant or parental lines) as well as two to three more
distantly related soybean lines. Representative results of all
three studies are shown. Results from some tests performed on
BASF soybean samples were previously presented;14 however,
none of the results shown here were previously published. For
each study we attempted to obtain human blood samples
(plasma or serum) from subjects with objective, clinically
confirmed allergies and verify the soybean-specific in vitro IgE
binding prior to study initiation. However, few clinical allergists
specializing in food allergy that were contacted had subjects
with confirmed food allergy to soybeans. One center in Berlin,
Germany, and one center in Zurich, Switzerland, provided a
number of clinical samples from subjects with documented
allergy to foods containing soybean products and with soybean-
specific IgE clearly above background levels based on the
standardized laboratory ImmunoCAP for soybean (f14) and/or
Gly m 4 (f353) from Phadia (now ThermoScientific, USA).
Some human samples had very low levels of soybean protein-
specific IgE based on preliminary direct binding using
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immunoblots from reducing and nonreducing SDS-PAGE or
direct binding to native protein by ELISA. Therefore, additional
samples of plasma were obtained from FDA-licensed blood
product suppliers from subjects that were screened by
questionnaire and indicated probable food allergy to soybean,
peanut, or other legumes and positive soybean-specific IgE
testing using the ImmunoCAP system (Table 3). The EU
values in Table 3 are for ImmunoCAP f14.
In all three studies diverse patterns of IgE binding were seen
between subjects as demonstrated in 1D immunoblots (Figure
Figure 1. Soybean-allergic IgE binding to reduced and nonreduced proteins in 1D SDS-PAGE; BPS-CV127-9 (BASF). (A) Proteins in extracts of
soybean (10 μg), navy bean (10 μg), peanut (2 μg), and maize (10 μg) were separated by SDS-PAGE under (a) reducing and (b) nonreducing
conditions and immunoblotted with sera from three soybean-allergic subjects LPSCH102, RGLEG103, or 719 and detected using hIgE-specific mAb
conjugated with HRP followed by ECL detection. Sample lanes: (1) 3410-I, null-segregant; (2) 3411-T, GM line BPS-CV127-9; (3) 3415-M,
MON8001; (4) 3416-C, CD217; (5) Conquista, parental line; (6) none; (7) navy bean; (8) none; (9) peanut; (10) none; (11) maize; (12 MW
marker. (B) Samples of purified human IgE and IgG were diluted and spotted onto nitrocellulose, representing from 1 pg−1 μg of immunoblobulin
and then detected using monoclonal anti-hIgE or anti-hIgG to demonstrate immunoglobulin specificity. (C) Protein samples of null-segregant 3410-
I GM, 3411-T, CD217, 3416-C, and Conquista (parental) soybean lines were separated by IEF in pI 3−10 nonlinear IPG strips then by size in SDS-
PAGE, blot incubated, with serum RGLEG103.
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1A). A few subjects exhibited binding to a single protein that is
most visible under reducing conditions (e.g., subject
LPSCH102), which may be a homologue of the LTP based
on similar binding to a corn protein at ∼12 kDa using this
subject’s sera. For many subjects moderately complex binding
was observed to at least three proteins including two that are
linked by disulfide bonds (e.g., subject RGLEG103), and
occasionally more complex patterns with binding to six or more
bands (e.g., subject 719) was seen. The last case likely includes
IgE binding to cross-reactive carbohydrate determinants
(CCD) on some of the soybean proteins as demonstrated by
strong binding to a protein of about 34 kDa (probably PHA,
Figure 2. Extracts of soybean samples from the Bayer LL55 study were separated by 1D gel SDS-PAGE under reducing and nonreducing conditions
as well as 2D gels (IEF first direction, pI 3−10 nonlinear gradient, then SDS-PAGE). Proteins in gels were stained with Coomassie blue. Proteins
from identically run gels were transferred to PVDF membranes for immunoblotting. Sample lanes (1D): (1) A5547 (near-isogenic); (2) LL55
(transgenic); (3) Stine 2686-6; (4) Stine 2788; (5) Stine 3000-0; (6) empty; (7) MW marker; (8) empty; (9) navy bean; (10) empty; (11) peanut;
(12) empty; (13) maize (corn). 2D gel samples: A5547 (isogenic); LL55 (transgenic); Stine 2686-6; Stine 2788.
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based on unpublished data) in navy bean extract and multiple
proteins in maize extract (Figure 1, subject 719). IgE binding to
CCD is rarely clinically relevant.29 Many serum and plasma
samples also showed IgE binding to at least one protein in the
control plant extracts of navy bean, peanut, or maize, and the
histories of most subjects (Table 3) indicated multiple food and
airway allergies. However, it is important to stress that IgE
binding alone does not prove that a given protein causes
allergic symptoms, only that IgE antibodies are able to bind to
the protein in vitro. Clinical laboratory results with positive
soybean-specific IgE binding (>1 kUA/L specific IgE) often
correlated with clear IgE binding detected in our study by
immunoblot and/or ELISA, but in a few cases low levels or no
detectable IgE binding was demonstrated even for subjects with
reported positive food challenges, although some of those
subjects (CC-3, CC-8, CC-11, CC-12, CC-15, CC-16)
exhibited binding to high concentrations of native total soybean
protein by dot-blot assay (data not shown). Whereas binding to
peanut proteins typically correlated with allergy to peanut,
binding to navy bean or maize was rarely matched with reports
of clinical allergy to those foods. The 1D IgE blots for the
BASF study of BPS-CV127-9 (3411-T) did not show obvious
qualitative or quantitative differences compared to the null-
segregant (3410-I) or the Conquista (parental line), but there
Figure 3. Serum IgE immunoblots of Bayer LL55 soybeans with soybean allergic plasma 18534-LN using 1D SDS-PAGE samples under reducing
and nonreducing conditions and 2D PAGE. Sample lanes (1D): (1) A5547 (near-isogenic); (2) LL55 (transgenic); (3) Stine 2686-6; (4) Stine
2788; (5) Stine 3000-0; (6) empty; (7) MW marker; (8) empty; (9) navy bean; (10) empty; (11) peanut; (12) empty; (13) maize (corn). The
notable difference in binding between soybean samples is at 50 kDa in nontransgenic sample lane 3 in reducing conditions, or lower MW in
nonreducing conditions of 1D gel blots, and spot 6 of sample Stine 2686-6 in 2D gel blots. The only visible difference between near-isogenic line
A5547 is the presence of light spot 7 in A5547 and the absence of the spot in LL55 (transgenic).
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were minor differences of all three of those relative to
commercial lines MON8001 (2415-M) and CD217 (3416-C)
as described by Panda et al.14 However, differences were not
observed using the three human samples shown in Figure 1A.
We previously observed that some anti-IgE secondary detection
antibodies can bind to IgG in immunoassays25 and that many
sera contain both IgG and IgE specific to dietary proteins (data
not shown). Therefore, the specificity of the SouthernBiotech
anti-IgE used in these studies was tested with reciprocal binding
to diluted IgE and IgG and demonstrated specificity of >10000
to 1 for IgE (Figure 1B).
Two-dimensional immunoblots of proteins separated first by
charge (pI value) and second by apparent mass (SDS-PAGE)
provide a much more detailed and complicated picture than is
obvious from 1D gels. Individual proteins and clusters of
proteins are visible in Figure 1C using serum RGLEG103,
compared to Figure 1A. Clearly the single visible bands in
Figure 1A (reducing) separate into clusters of proteins with
multiple pI values (e.g., 22, 37, and 47 kDa) that can show
minor variations, primarily in intensity, between soybean lines
(Figure 1C). However, new spots (circled as 18 and 19 in 2D
gel blots Figure 1C) of CD217 (3416-C) were not visible in
lane 4 under either reducing or nonreducing conditions from
Figure 4. Serum IgE immunoblots to Bayer LL55 soybeans with soybean allergic plasma 20197-BH using 1D SDS-PAGE samples under reducing
and nonreducing conditions and 2D PAGE. Sample lanes (1D blots): (1) A5547 (near-isogenic); (2) LL55 (transgenic); (3) Stine 2686-6; (4) Stine
2788; (5) Stine 3000-0; (6) empty; (7) MW marker; (8) empty; (9) navy bean; (10) empty; (11) peanut; (12) empty; (13) maize (corn). No
obvious difference in binding between soybean samples was visible from 1D blots beyond the more intense band at 250 kDa in the three commercial
lines (lanes 3−5). A few low-intensity spots differed in 2D PAGE blots. Two spots that were visible in LL55 transgenic in circle 11 were not visible in
the A5547 nontransgenic line but were also visible in both D and E samples. In addition, the faint spots in circles 14 and 15 were visible in D and E,
but not the LL55 transgenic or nontransgenic A5547.
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1D immunoblots (Figure 1A). This commercial line is not
known to be more allergenic than the other lines. Additional
minor differences in the numbers of spots visible from an
apparent series of likely post-translationally modified similar
proteins (e.g., circle 4 in Figure 1C) are unlikely to represent
any significant difference in overall IgE binding or allergy
between soybean lines. Interpretation of these blots is complex.
Although other investigators have shown that larger gel formats
(13 cm IEF strips compared to our 7 cm strips) increase
discrimination of spots, we find it is impossible to obtain a
sufficient volume of serum from individual donors to be able to
perform multiple immunoblots with the larger format.
However, results showing minimal differences in 1D (reducing
and nonreducing conditions) and 2D immunoblots as well as
ELISA inhibition of the BASF soybean lines led us to conclude
it is highly unlikely there are biologically relevant differences in
the allergen content of the GM, near-isogenic, parental, or
other commercial soybean lines.14
Evaluation of the allergen content of Bayer’s LL55 was
performed by comparison of IgE from soybean-allergic subjects
to bind to proteins in the transgenic, parental lines and three
other nontransgenic commercial soybean lines by immunoblot
comparisons of 1D SDS-PAGE with proteins in extracts
separated under reducing and nonreducing conditions.
Immunoblots of 2D gel separated proteins of transgenic,
parental line and two (of the three) other commercial soybean
lines were also tested. Protein separation patterns are
demonstrated by Coomassie blue staining in gels shown in
Figure 2. The same extracts were separated in identical gels and
the proteins transferred to PVDF membranes prior to blocking
and incubation with samples from allergic subjects or controls.
Bound IgE was detected as described for the BASF study.
Representative results are shown in Figures 3 and 4. Plasma
18534-LN revealed minor differences in the intensity of binding
to some proteins in the nontransgenic control A5547 and
transgenic LL55 in 1D immunoblots, but the most notable
difference was the intense binding to a band at approximately
Figure 5. SDS-PAGE IgE Immunoblots from FG72 study using reducing and nonreducing gels. Minor differences in band intensity are obvious
between some samples. Soybean sample loading: (1) FG72; (2) Jack (parental); (3) Stine 2686-6; (4) Stine 2788; (5) Stine 3000-0. Control lanes
(navy bean, peanut, and maize) are not presented to allow presentation of blots using four soybean allergic human samples (plasma samples 19392-
CS, 20197-BH, and 9735-RE; as serum CC10). A minor additional band was present at about 20 kDa in lane 3 (∼45 kDa) of reducing sample with
plasma 9735-RE. A major higher MW smear and visible band at 75 kDa in lane 3 of nonreducing sample with serum CC 10 is likely due to the
presence of a conformational epitope on a 75 kDa protein that is abolished by reduction with 2-mercaptoethanol. That observation was also made
with a number of other serum samples (not shown). Other differences seem to represent minor concentration differences of specific protein bands,
although in some cases differences may be artifacts of protein transfer. These human samples were used in the serum pool for ELISA inhibition tests.
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45 kDa in reducing and intense multiple bands in non-
transgenic sample in lane 3, sample D (Stine 2686-6) of both
reducing and nonreducing samples, which was not present in
any of the other four soybean lines. The intense binding to a
band of approximately 34 kDa in the navy bean sample (lane 9
of both 1D reducing immunoblots) corresponds to phytohe-
maglutinin (PHA) and likely represents IgE binding to complex
carbohydrate determinants on PHA (unpublished inhibition
data). By 2D immunoblot, the fairly weak IgE binding spot
marked 7 on the A5547 immunoblot was not present in the
transgenic or the other two commercial soybean lines. We did
not have a sufficient volume of serum to attempt inhibition of
binding to the soybean sample Stine 2686−-6 and kidney bean
by preincubating the serum with kidney bean extract, which
would confirm that CCD was the likely source of binding.
Plasma sample 20197-BH (Figure 4) showed slightly weaker
binding to the very high MW band at 220−240 kDa in both
nontransgenic lane 1 and transgenic lane 2 compared to more
intense binding to the same MW band in the three
nontransgenic commercial lines (lanes 3−5). Because the
reduced samples (left blot) do not show the high MW band
(220 kDa) and rather show intense bands at ∼50 and 75 kDa,
the high MW band in the nonreduced blot probably
corresponds to the trimeric form of β-conglycinin, which is
expected to be reduced to two subunits of about 70 kDa and
one of about 50 kDa, corresponding to α-, α′-, and β-subunits
of β-conglycinin (not yet confirmed by protein sequencing). In
the 2D immunoblot of LL55, two moderately faint spots are
Figure 6. FG72 soybean study: allergic subjects’ direct and inhibition IgE ELISA. The four highest IgE binding sera (of 10) by immunoblotting and
preliminary ELISA were retested to guide dilution of individual samples for the inhibition pool. Raw optical density (OD) values are reported for
individual human samples with direct binding indicated; 19392-CS was 4 times as high in soybean-specific IgE as the second highest binding sample,
and immunoblot results demonstrated at least three major bands (Figure 5), whereas the lower binding samples (20197-BH, 9735-RE, and CC10)
primarily bound to different single proteins. Inhibition ELISA assays were performed in triplicate using a pool of four subjects (0.25 volume of
19392-CS to 1 volume of each of the other three human samples). ELISA plates were coated with an equal protein pool of the five soybeans
(parental, Jack; FG72, Stine 2686-6, Stine 2788, and Stine 3000-0) for both direct binding and inhibition. For inhibition the pooled serum/plasma
was preincubated (1 h) with diluted samples of the standard pool or individual soybean extracts prior to incubation with the coated sample wells,
then washed and incubated with anti-IgE, washed again, and finally substrate. The amount of protein of each extract required to achieve 50%
inhibition of maximum IgE binding is shown in the table and is the reciprocal of “relative potency”. Thus, FG72 is the weakest at inhibiting IgE
binding, although there were no significant differences between extracts.
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visible in circle 11 that are not visible in the nontransgenic
A5547 sample. However, the same spots are visible in the two
nontransgenic Stine lines, suggesting this is not unique to
transgenic LL55. In addition, both Stine soybean lines showed
two additional faint spots marked 14 and 15 that are not visible
in either nontransgenic A5547 or transgenic LL55. The other
eight sera and plasma samples showed similar patterns of IgE
binding between the transgenic LL55 and nontransgenic A5547
lines. We did not perform a quantitative analysis (ELISA
inhibition) in the study of A5547, but the qualitative results of
1D immunoblots under reducing and nonreducing conditions
and 2D immunoblots indicated that differences in IgE binding
to LL55 are remarkably similar to binding to nontransgenic
comparator line and other commercial soybean lines. It is
therefore highly unlikely that there is any significant difference
in the allergen content of the transgenic and nontransgenic
soybeans for LL-55.
The final study described here evaluated IgE binding to
FG72 transgenic soybean line compared to nontransgenic
parental Jack and three other nontransgenic commercial lines
(Stine 2686-6, Stine 2788, and Stine 3000-0) using 1D
immunoblotting and ELISA inhibition. Representative 1D
immunoblots (Figure 5) are shown using the four soybean-
allergic subjects’ serum or plasma samples that were used as a
pool in ELISA inhibition. The banding patterns demonstrated
very different IgE protein binding patterns between human
donors, but qualitatively similar results across soybean lines.
Interestingly, IgE from donor 19392-CS bound to a protein of
approximately 50 kDa under reducing conditions as did IgE
from donor 20197-BH. However, under nonreducing con-
ditions donor 20197-BH IgE bound to lower molecular weight
proteins at 32 and 15 kDa, which does not correlate with results
from donor 19392-DS. The other prominent bands bound by
donor 19392 under reducing conditions were not prominent
bands in blots of 20197-BH. Under nonreducing conditions the
donor 19392-CS also showed considerable binding to bands at
150, 100, and 50 kDa that were not recognized as prominent
binding bands for donor 20197-BH. The rather faint band at
230 kDa in the nonreducing blot of donor 20197-BH may
represent the complexed trimeric β-conglycinin under non-
reducing conditions, and the 50 kDa band under reducing
conditions may represent IgE binding to β-conglycinin. The
prominent IgE binding bands from donor 9735-RD at
approximately 75 kDa in both reducing and nonreducing
blots likely represents a unique, nonseed storage protein that
does not include any disulfide bonds. However, the lower MW
and modest binding to a 70 kDa protein under nonreducing
conditions likely represent binding to a monomeric subunit of
glycinin that is reduced to acidic and basic subunits under
reduction (35 and 13 kDa). With these four soybean-allergic
subjects the differences in IgE binding by immunoblotting were
minor across soybean lines for all four donors, with the
exception of a 75 kDa band using serum CC-10 (lane 3,
nontransgenic control). This band is visible under nonreducing
conditions and is not replicated in other soybean lines. It was
also not visible under reducing conditions. It is therefore likely
to represent a conformational epitope that is dependent on a
disulfide bond.
The total IgE binding to native soybean proteins for each
clinical subject used to create a pool of serum for quantitation
of IgE binding in the FG72 study was measured by direct
ELISA (Figure 6, top panel). Clearly, donor 19392-CS had the
highest total IgE against soybean proteins with an absorbance
value nearly 4 times that of 20197-BH and >10 times higher
than those of 9735-RE and CC10. Because of these differences,
the volume of plasma 19392-CS was reduced to one-fourth of
the volume used from the other three soybean-allergic subjects
as the pool for the inhibition tests to reduce bias in the ELISA
inhibition assay. These four subjects each presented a different
IgE binding pattern in 1D immunoblots, demonstrating
different protein recognition with the adjusted volume ratios
provided a balanced pool for relative potency comparison in the
inhibition assay. Inhibition ELISA tests were performed in
triplicate, and results are compiled in the bottom panel of
Figure 6 for each soybean sample. Six concentrations of
inhibitor were tested for each extract of soybean lines, and the
amount of protein from each extract needed to achieve 50%
inhibition (EC50) was calculated for each sample as listed in
the inset (Figure 6). There were no statistically significant
differences in EC-50 values. However, of interest is the tailing
off of inhibition using extract Stine 2686-6 at the higher
concentrations of extract. This suggests a low-affinity
interaction of IgE from the pool for some protein(s) in that
extract. This result correlates with the extract (Stine 2686-6)
that was lost in reduced samples. This finding of IgE binding to
only nonreduced samples by 1D immunoblotting was also
observed for most of the other serum samples from the EU
(data not shown).
Focusing on the question of comparing IgE binding between
the transgenic and nearest genetic soybean line, there were no
marked differences in IgE binding to transgenic and non-
transgenic soybean lines in the three studies reported here. By
including other commercial non-GM soybean lines, we can
conclude that the variation was well within the range of binding
differences likely to be found in commercial lines of soybeans
that are used in foods today. Our conclusion is that there were
no data to suggest these three GM soybean lines differ in
endogenous allergen content from their nearest non-GM
counterparts or other tested commercial lines.
It is important to recognize the complexity of performing
these tests. It is very difficult to identify appropriate serum IgE
donors that have clearly recognized soybean food allergy as well
as significant levels of soybean protein-specific IgE binding.
Furthermore, the tests including 1D immunoblots, 2D
immunoblots, and ELISA inhibition provide somewhat differ-
ent answers in binding to proteins. The differences likely
depend on the structural epitopes that are bound, whether
conformational, sequential, or binding of IgE to CCD epitopes.
Due to the difficulty in obtaining relevant allergic sera and
the complexity of interpreting results when using subjects with
varied IgE sensitization patterns, some scientists have suggested
using non-antibody-dependent proteomic approaches to
evaluate potential changes in protein expression in a GM
crop relative to near-isogenic or commercial varieties as
described by Rouquie et al.30 A quantitative proteomics
approach using labeled peptide controls in a non-gel-based
evaluation method demonstrated high accuracy in measuring
concentrations of eight allergenic soybean proteins.31,32
However, the methods are technically challenging and measure
only specific peptide fragments from identified allergens, not
IgE binding or allergenicity. Measurement of allergens across
four genetically different soybean lines and in another study
across growing conditions demonstrated that some allergenic
proteins varied little, whereas one of the proteins varied up to
10-fold across environments.31 To be useful in the context of
endogenous allergen evaluation, one should know all of the
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allergenic proteins in a complex commodity and preferably the
relative allergenic potency of the individual components. The
methods should be capable of measuring all variables in protein
structure that might be relevant to IgE binding and elicitation
of allergy. Even more importantly, these tests demonstrated
that there is wide variation in allergen expression in non-GM
soybean varieties and lots used in commerce today. Regulatory
tests for allergen levels are not required for non-GM soybean
varieties.
In light of the complexity of performing tests to evaluate
endogenous allergens and the reality of commodity crop food
production, trade, and food processing, we do not believe the
types of studies we have described here add substantial
information to the safety assessment of GM commodity
crops except in cases when there are reasons to suspect
differences. If the transgene inserted into a GM crop was a
transcription factor or the transgenic event was intended to
reduce the allergenicity of the commodity crop, then tests
evaluating endogenous allergen content should be required.
At this time there is not good agreement about the exact
methods that should be used to perform tests to compare
endogenous allergen content. There has also not been
discussion about how much difference is too much or about
developing data to set boundaries of acceptability on potential
changes in allergen content of commodity crops. At the current
time, those involved in testing and those involved in regulation
of GM crops have rather quietly been looking for “statistically
significant differences” between the quantitative IgE binding to
proteins in the GM and near-isogenic line, as well as an absence
of qualitative differences (no new bands or spots), to conclude
that there are no concerns that a GM event is acceptable
regarding allergy. The expectation stems from the principles of
substantial equivalence that were intended to ensure a new GM
crop would be suitable in nutritional and antinutritional
properties to the crop varieties in current use as discussed by
Codex (2003).1 However, we do not have data to demonstrate
heightened risk of food allergies based on differences of allergen
expression between crops. One could argue that the same
criteria used to evaluate standardized allergenic extracts
(pharmaceutical products) might be suitable to use as a very
conservative guide for food safety. Regulators of standardized
allergen extracts used for diagnostic testing or immunotherapy
in the United States and EU have established limits of
acceptance of approximately 2-fold for claims by manufacturers
of those products that they are equivalent for diagnosis or
immunotherapy.27,33 Those criteria were established for
allergenic extracts intended for diagnosis or treatment
(immunotherapy) of allergic disease. However, even a 2-fold
difference is arguably too small for defining food safety if the
variation in allergen content is at least 15-fold for LTP in
commercial corn and uncertain for most allergenic crops. An
additional consideration is that most of the common and
potent food allergens (proteins) are major components of the
food source. Thus, there are limits to the amount of increased
accumulation the major peanut allergens (Ara h1, Ara h2, Ara
h3, Ara h6) or soybean allergens (glycinins and β-conglycinins)
that can occur in a given food grade material. Many of these
proteins represent 2−20% of the protein in the food. Clearly,
expression of any major component cannot increase more than
a few-fold without influencing the expression of other proteins
or the characteristics of the food material.
Perspective could also be gained from procedures used by
recognized clinical food allergists and scientists involved in
double blind, placebo-controlled tests attempting to define
threshold doses for food allergy for individuals as presented by
Crevel et al.34 The common guideline is to start food challenges
of individuals suspected of having severe allergies at a very low
dose of total allergenic food (e.g., peanut), such as 10 μg. Dose,
and observe for 20 min, then increase the dose by from 2- to 5-
fold at each succeeding step of active (allergen) dose.
Controlled clinical studies following this protocol have been
deemed safe by ethical boards and clinicians and rarely lead to
systemic anaphylaxis if stopped at the dose that caused
objective allergic symptoms in the individual.34 This
information suggests that a 2−5-fold increase in total allergen
dose in a given commodity crop is highly unlikely to
significantly increase the risk of food allergy for those with
severe allergic disease.
The process of clinical risk management for food-allergic
subjects over the past 20 years has been to identify the specific
food causing allergy for the individual and have them avoid
consuming foods that contain any of the allergenic food,
whether it is peanut, soybean, milk, eggs, wheat, or corn. Food
companies are required to label ingredients of packaged foods
with special attention given to any ingredient that might
contain proteins from the most common allergic foods. The
allergic consumers are informed about foods to avoid and how
to interpret food labels. Nonallergic consumers can consume
large quantities of the same food without adverse effects. There
is risk of severe food allergy, but that is from unlabeled or
inaccurately labeled foods, not from minor differences in the
expression of allergens within the allergenic commodity crop.
It seems quite logical, then, to use the collective information
in deciding on the appropriate need to test for changes in
endogenous allergen expression in GM crops relative to the
non-GM counterpart. It should rarely be necessary, based on
public health risks, as food sources should be labeled and
allergic consumers should avoid consuming foods containing
their allergen. In cases when regulators deem such tests are
necessary, limits should be established that reflect the natural
variation of allergens in commonly used varieties of the same
food crop. A doubling of allergen content would be acceptable
for a pharmaceutical product intended to be used to diagnose
or treat those with allergies. An additional factor that should be
recognized is the most likely and deleterious risk of food allergy
that might occur from creation of a new GM crop would be
introducing an existing allergen or highly cross-reactive protein
from a different source.12,35 The evaluation process and testing
to prevent the risk of transferring an allergen is well established
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